HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure

This publication has 32 references indexed in Scilit:

• Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy
  Hepatology Communications, 2021
• Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America
  Hepatology, 2021
• Letter to the Editor: Examining HBV‐RNA Kinetics During NA Treatment—Are NAs Multifunctional Antiviral Agents?
  Hepatology, 2021
• Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
  Journal of Hepatology, 2020
• Pregenomic HBV RNA and Hepatitis B Core‐Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy
  Hepatology, 2019
• HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues
  Journal of Hepatology, 2019
• Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels
  Journal of Hepatology, 2018
• Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog‐Treated or Untreated Patients During Chronic and Acute Infection
  Hepatology, 2018
• Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors
  Hepatology, 2014
• Hepatitis B virus clearance rate estimates
  Hepatology, 2009